Zimmer Biomet (ZBH) financial statements
+111.2%since 2007
- FY2025 revenue
- $8.2B▲ +7.2%
- FY2025 net income
- $705M▼ −22.0%
- FY2025 diluted EPS
- $3.55▼ −19.9%
- FY2025 free cash flow
- $1.5B▲ +13.7%
Zimmer Biomet income statement
| USD millions | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Period ended | 31 Dec 2025 | 31 Dec 2024 | 31 Dec 2023 |
| Revenue | 8,232 | 7,679 | 7,394 |
| Operating income | 1,098 | 1,286 | 1,278 |
| Pretax income | 831 | 1,037 | 1,067 |
| Net income | 705 | 904 | 1,024 |
| Diluted earnings per share | 3.55 | 4.43 | 4.88 |
Zimmer Biomet balance sheet
| USD millions | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Period ended | 31 Dec 2025 | 31 Dec 2024 | 31 Dec 2023 |
| Cash and cash equivalents | 592 | 526 | 416 |
| Total assets | 23,092 | 21,365 | 21,497 |
| Total liabilities | 10,386 | 8,889 | 9,009 |
| Total equity | 12,706 | 12,476 | 12,488 |
| Long-term debt | 6,932 | 5,342 | 4,868 |
Zimmer Biomet cash flow statement
| USD millions | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Period ended | 31 Dec 2025 | 31 Dec 2024 | 31 Dec 2023 |
| Operating cash flow | 1,697 | 1,499 | 1,582 |
| Capital expenditure | -224 | -204 | -291 |
| Free cash flow (derived) | 1,473 | 1,296 | 1,291 |
| Dividends paid | -190 | -196 | -201 |
| Share repurchases | -487 | -868 | -692 |
Quarterly highlights
| USD millions | Q3 FY2026 | Q2 FY2026 | Q1 FY2026 | Q4 FY2025 |
|---|---|---|---|---|
| Period ended | 30 Sep 2026 | 30 Jun 2026 | 31 Mar 2026 | 31 Dec 2025 |
| Revenue (derived) | 2,063 | 2,177 | 2,087 | 2,244 |
| Operating income (derived) | 308 | 326 | 373 | 155 |
| Net income (derived) | 192 | 198 | 238 | 139 |
| Diluted earnings per share | 1.00 | 1.03 | 1.22 | n/a |
| Operating cash flow (derived) | 560 | 448 | 359 | 517 |
| Total assets | 23,539 | 22,798 | 22,722 | 23,092 |
Zimmer Biomet major shareholders
| Holder | Share of class | Shares | Filed |
|---|---|---|---|
| Dodge & Cox | 12.5% | 24,124,735 | 14 August 2026 |
| BlackRock, Inc. | 7.8% | 15,573,187 | 17 April 2025 |
| Vanguard Capital Management | 7.5% | 14,767,527 | 30 April 2026 |
| Capital International Investors | 6.4% | 12,438,366 | 12 August 2026 |
| HARRIS ASSOCIATES L P | 6.2% | 12,264,703 | 18 February 2026 |
Zimmer Biomet 10-K and SEC filings
| Filed | Form | Type | Description |
|---|---|---|---|
| 12 November 2026 | 8-K | Current report | Current report |
| 4 November 2026 | 10-Q | Quarterly report | Quarterly report |
| 4 November 2026 | 8-K | Current report | Current report |
| 8 September 2026 | 8-K | Current report | Current report |
| 5 August 2026 | 8-K | Current report | Current report |
| 5 August 2026 | 10-Q | Quarterly report | Quarterly report |
| 5 August 2026 | 8-K | Current report | Current report |
| 29 June 2026 | 8-K | Current report | Current report |
Common questions
What was Zimmer Biomet's revenue in fiscal 2025?
Zimmer Biomet reported $8.2 billion in revenue for fiscal 2025, the year ended 31 December 2025, up 7.2% from fiscal 2024.
What was Zimmer Biomet's net income in fiscal 2025?
Zimmer Biomet reported net income of $705 million for fiscal 2025, the year ended 31 December 2025, down 22.0% from fiscal 2024. Diluted earnings per share were $3.55.
What was Zimmer Biomet's free cash flow in fiscal 2025?
Zimmer Biomet had $1.5 billion in free cash flow in fiscal 2025. Operating cash flow was $1.7 billion and capital expenditure was $225 million.
What were Zimmer Biomet's total assets at the end of fiscal 2025?
Zimmer Biomet reported total assets of $23.1 billion at the end of fiscal 2025, the year ended 31 December 2025.
How much Zimmer Biomet history do I get?
Every account gets the full history, annual and quarterly, with first reported values and as of dates.
Start with a free key
Free $10 credits every month, no card.Free $10 credits a month, no card.